• Diclofenac sodium, a phenylacetic acid derivative, is a non-steroidal compound with pronounced antirheumatic, anti-inflammatory, analgesic and antipyretic properties. 
  • It inhibits prostaglandin biosynthesis which plays a major role in causing inflammation, pain and fever. Medication with Diclofenac sodium can relieve the symptoms of inflammation, but can not cure the cause. In rheumatic diseases, Diclofenac sodium elicits a clinical response characterized by marked relief from signs and symptoms such as pain at rest, pain on movement, morning stiffness, and swelling of the joints, as well as by an improvement in function. 
  • Diclofenac is almost completely absorbed. Food has no clinical relevant influence on the absorption and bioavailability of Diclofenac
  • No accumulation occurs provided the recommended dosage intervals are observed even in patients suffering from renal impairment.
  • 99.7% of  Diclofenac is bound to serum proteins. It enters the synovial fluid, and reaches higher levels in the synovial fluid than in the plasma and remain higher for up to 12 hours. 
  • Diclofenac is subject to first-pass metabolism and then excreted mainly in the urine (about 65%) but also in the bile (about 35%).

Each Suppository  of  Dicloban® 25 contains:

  • Diclofenac sodium     25 mg

Each Suppository  of  Dicloban® 12.5 contains:

  • Diclofenac sodium     12.5 mg

Dicloban® is used in:

  • Inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis)
  • Painful syndromes of the vertebral column. 
  • Non-articular rheumatism. 
  • Post-traumatic and postoperative pain, inflammation, and swelling. 
  • Painful and inflammatory conditions in gynaecology, e. g. primary dysmenorrhea or adnexitis.    
  • Soft tissue injuries: sprain and strain 
  • Acute infectious diseases, especially of the ear, nose and throat. 
  • Dental pain, renal and biliary colics.
  • Acute gout and Juvenile rheumatoid arthritis.

 Dicloban® should not be given to:

  • Patients with hypersensitivity to Diclofenac sodium
  • Patients with peptic ulcer and to patients who have experienced asthma, urticaria, or other allergic-type reactions caused by Aspirin or other NSAID. 
  • Dicloban® may reduce the efficacy of diuretics. 
  • Concomitant treatment with a potassium-sparing diuretic may be associated with increased serum potassium levels, which should therefore be monitored frequently. 
  • Patients taking Dicloban® and are also receiving (Digoxin, Methotrexate, Cyclosporin or Lithium) should be observed for potential development of the specific toxicities of these drugs. 
  • Concomitant administration of other systemic NSAIDs or Glucocorticoids may increase the occurrence of side effects. 
  • Cholestyramine appears to reduce the bioavailability of Diclofenac when the two drugs are given together; Colestipol produces a similar action but smaller effect. 
  • Owing to the possibility of uterine inertia and/or premature closure of the ductus arteriosus, Dicloban® should not be used in the third trimester. 
  • Dicloban® passes into breast milk, but in quantities so small to be harmful to a breast-fed infant. 

*is generally well tolerated.

*The most common side effects include:-

  • gastro-intestinal disturbances
  • headache
  • dizziness
  • fluid retention
  • liver function disorders
  • rash and pruritis have been reported. 

* The dose should be adjusted to the patient’s response, tolerance and severity of symptoms. 

* Dicloban® capsules or tablets should be swallowed whole with plenty of  liquid preferably during or  after meals. 


-The recommended daily dosage is 75–150 mg as the following:

  • One capsule of Dicloban® SR 100 per day during long term treatment. 
  • Or 1–3 enteric coated tablets of Dicloban® 25 or 50 daily in 2–3 divided doses.
  • In primary dysmenorrhoea the daily dosage should be individually adjusted and generally 50–150 mg.


-The initial dose for children aged 6 years and over:

  • 2–3 mg/kg body weight / day, in 2–3 divided doses.
  • The dose range is between 0.5-2 mg/Kg body weight daily, according to the severity of the case.
  • In case of juvenile rheumatoid arthritis, the dose can be increased to 3 mg/Kg body weight daily on 2-3 divided doses.
  • Dicloban® should not be given to children under 12 months of age.
  • Or as directed by the physician.

 Dicloban® should be used with caution:

  • In patients with impaired hepatic or renal function
  • In patients with history of cardiovascular diseases and peptic ulcer.

Dicloban® 25 mg and 12.5 mg Suppository : 

  • (Blisters of 5 Suppository  , Packs of one blisters.)
  • Store in a dry place at a temperature below 25°C.
  • Protect from moisture and light.